FMED
Price
$32.74Alerts
Change
-$0.02 (-0.06%)
Updated
Nov 12 closing price
Net Assets
30.3M
Intraday BUY SELL Signals
KROS
Price
$11.08Alerts
Change
-$0.31 (-2.72%)
Updated
Nov 20 closing price
Capitalization
185.58M
102 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FMED vs KROS

FMED vs KROS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
FMED vs. KROS commentary
Nov 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FMED is a Hold and KROS is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for FMED with price predictions
Nov 20, 2026

FMED's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for FMED turned positive on November 09, 2026. Looking at past instances where FMED's MACD turned positive, the stock continued to rise in 29 of 33 cases over the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on FMED as a result. In 49 of 59 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

FMED moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for FMED crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.

Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where FMED advanced for three days, in 171 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

The Aroon Indicator entered an Uptrend today. In 124 of 143 cases where FMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

FMED broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
a Summary for KROS with price predictions
Nov 20, 2026

KROS in upward trend: price rose above 50-day moving average on November 17, 2026

KROS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend. In 39 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KROS's RSI Indicator exited the oversold zone, 29 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on KROS as a result. In 75 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

The Moving Average Convergence Divergence (MACD) for KROS just turned positive on November 17, 2026. Looking at past instances where KROS's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.

Following a +19.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 224 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The 10-day moving average for KROS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

KROS broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for KROS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.707) is normal, around the industry mean (3.596). P/E Ratio (-2.907) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
KROS: Fundamental Ratings
KROS
OUTLOOK RATING
1..100
35
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
56
P/E GROWTH RATING
1..100
98
SEASONALITY SCORE
1..100
27

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FMEDKROS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 12 days ago
84%
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 10 days ago
83%
Bearish Trend 2 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement

FMED and

Correlation & Price change

A.I.dvisor indicates that over the last year, FMED has been loosely correlated with BNTX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if FMED jumps, then BNTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FMED
1D Price
Change %
FMED100%
N/A
BNTX - FMED
49%
Loosely correlated
-0.52%
VRTX - FMED
47%
Loosely correlated
-1.08%
IMVT - FMED
46%
Loosely correlated
-2.31%
DYN - FMED
46%
Loosely correlated
-3.31%
KROS - FMED
45%
Loosely correlated
-2.72%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HDLB16.010.07
+0.43%
ETRACS Monthly Pay 2xLeveraged US High Dividend Low Volatility ETN Series B (HDLB)
DURA38.93-0.23
-0.59%
VanEck Durable High Dividend ETF (DURA)
DJUL48.56-1.03
-2.07%
FT Vest U.S. Equity Deep Buffer ETF - July (DJUL)
MFEM22.49-1.23
-5.18%
PIMCO RAFI Dynamic Multi-Factor Emerging Markets Equity ETF (MFEM)
ARTY53.94-5.50
-9.25%
iShares Future AI & Tech ETF (ARTY)